BAFNAPHARM Intraday Analysis...

BAFNAPHARM Share Price

Open 27.00 Change Price %
High 28.00 1 Day -0.20 -0.74
Low 25.70 1 Week -7.20 -21.18
Close 26.80 1 Month -7.20 -21.18
Volume 5273 1 Year -7.20 -21.18
52 Week High 28.60
52 Week Low 25.70
BAFNAPHARM Important Levels
Resistance 2 28.93
Resistance 1 28.05
Pivot 26.83
Support 1 25.55
Support 2 24.67
NSE INDIA Most Active Stocks
JPASSOCIAT 17.65 -4.85%
IBREALEST 254.15 5.15%
ITC 267.85 0.32%
ITC 267.85 0.32%
SUZLON 16.75 -0.89%
UNITECH 7.00 -2.10%
TATAMOTORS 423.65 4.62%
RCOM 20.10 -0.50%
KSK 12.00 2.13%
KSK 12.00 2.13%
More..
NSE INDIA Top Gainers Stocks
INDIAGLYCO 260.45 20.00%
HIRECT 123.95 19.99%
SILINV 225.20 19.98%
CGCL 120.15 19.97%
NELCO 125.55 19.97%
ASAL 93.15 19.96%
DHARSUGAR 27.65 19.96%
JAICORPLTD 132.80 19.96%
PRATIBHA 10.65 19.66%
VASWANI 22.40 19.47%
More..
NSE INDIA Top Losers Stocks
SPYL 0.30 -14.29%
XLENERGY 1.70 -10.53%
COMPUSOFT 14.95 -9.67%
UVSL 0.50 -9.09%
BRNL 194.50 -6.69%
ZODIACLOTH 189.85 -6.66%
SMPL 1.50 -6.25%
CNOVAPETRO 46.20 -6.19%
RTNPOWER 6.20 -6.06%
ONWARDTEC 115.00 -5.47%
More..

Bafna Pharmaceuticals Limited (NSE: BAFNAPHARM)

BAFNAPHARM Technical Analysis 5
As on 19th Sep 2017 BAFNAPHARM Share Price closed @ 26.80 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 30.14 & Strong Sell for SHORT-TERM with Stoploss of 30.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
BAFNAPHARM Target for September
1st Target up-side 31.56
2nd Target up-side 34.15
3rd Target up-side 36.75
1st Target down-side 24.14
2nd Target down-side 21.55
3rd Target down-side 18.95
BAFNAPHARM Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 46.48 Sideways
MFI (14) MFI is 69.18 Sideways
CCI (20) CCI is -27.70 Sideways
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Short Sell 31.94
10 Day Avg Volume Traded -87.47 % Less then 10 Day Average Volume
BAFNAPHARM Other Details
Segment BE
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
BAFNAPHARM Address
BAFNAPHARM
N/A
BAFNAPHARM Latest News
BCCL to invest around $3.2M in Lifezen Healthcare   VC Circle   - 19th Mar 15
Bafna Pharmaceuticals clears renewal audit by MHRA-UK   Equity Bulls   - 04th Mar 15
Bafna Pharma stock rallies 8%   Indiainfoline   - 02nd Mar 15
Strides Arcolab acquires majority stake in Bafna Pharma   Daily News & Analysis   - 22nd Jul 14
Bafna Pharmaceuticals Limited   Moneycontrol.com   - 26th Nov 13
Bafna Pharmaceuticals recommends 6% dividend for 2012-13   Economic Times   - 22nd May 13
Bafna Pharma's Raricap sales double in FY13   Myiris.com   - 10th May 13
Bafna Pharma Obtains Ghana FDA Nod To Market Omeran Capsules   RTT News   - 03rd May 13
Bafna Pharma to focus on haematinic drug mkt   Business Standard (blog)   - 13th Apr 11
Bafna Pharma: Stock provides little incentives   Economic Times   - 04th Apr 11
Interactive Technical Analysis Chart Bafna Pharmaceuticals Limited ( BAFNAPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Bafna Pharmaceuticals Limited
BAFNAPHARM Business Profile
Bafna was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. During the year 1995, Bafna Pharmaceuticals Limited was incorporated and it acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine. Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The current market capitalization stands at Rs 49.07 crore. The company has reported a standalone sales of Rs 46.99 crore and a Net Profit of Rs 1.19 crore for the quarter ended September 2013. The company management includes Bafna Mahaveer Chand - Chairman & Managing Director, Paras Bafna - Whole Time Director, Sunil Bafna - Ind. Non-Executive Director, V Rajamani - Ind. Non-Executive Director, R Dwarakanathan - Ind. Non-Executive Director, Kamlesh Kumar - Ind. Non-Executive Director. The Registered office is at Bafna Towers, New No.68, Old No. 299, Thambu Chetty Street, Chennai (Madras), Tamil Nadu - 600001.